Adopting STING agonist cyclic dinucleotides as a potential adjuvant for SARS-CoV-2 vaccine
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
A novel STING agonist CDG SF unilaterally modified with phosphorothioate and fluorine was synthesized. CDG SF displayed better STING activity over dithio CDG. Immunization of SARS-CoV-2 Spike protein with CDG SF as an adjuvant elicited an exceptional high antibody titer and a robust T cell response, which were better than the group using aluminium hydroxide as a adjuvant. These results highlighted the adjuvant potential of STING agonist in SARS-CoV-2 vaccine preparation for the first time.
Article activity feed
-
SciScore for 10.1101/2020.07.24.217570: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Mice used in the experiments were raised in Animal Facility of Center of Biomedical Analysis in Tsinghua University and treated in compliance with the animal ethics guidelines. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable SARS-CoV-2 vaccines immunization: 6-8 week old Babl/c mice (4-5 mice per group, female) were separately subcutaneously vaccinated with SARS-CoV-2 S protein 5 μg/mouse, CDGSF 20 μg/mouse, Alhydrogel® adjuvant 2% 100 μg/mouse. Cell Line Authentication Authentication: Animal Facility of Center of Biomedical Analysis in Tsinghua University has been authenticated by Association for … SciScore for 10.1101/2020.07.24.217570: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Mice used in the experiments were raised in Animal Facility of Center of Biomedical Analysis in Tsinghua University and treated in compliance with the animal ethics guidelines. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable SARS-CoV-2 vaccines immunization: 6-8 week old Babl/c mice (4-5 mice per group, female) were separately subcutaneously vaccinated with SARS-CoV-2 S protein 5 μg/mouse, CDGSF 20 μg/mouse, Alhydrogel® adjuvant 2% 100 μg/mouse. Cell Line Authentication Authentication: Animal Facility of Center of Biomedical Analysis in Tsinghua University has been authenticated by Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) Table 2: Resources
Antibodies Sentences Resources Then, cells were harvested and strained with mouse anti-CD86-phycoerythrin antibodies (BD Pharmingen, dilution 1/200) at ice for 1h. anti-CD86-phycoerythrinsuggested: NoneAfter washing again, diluted rabbit anti-mouse IgG-Peroxidase antibodies (1/2000 dilution, Sigma) were added to each well (100 μL per well) and incubated for 1h at 37°C. anti-mouse IgG-Peroxidasesuggested: NoneAfter washing with PBS and PBST, isotype antibodies IgG1, IgG2a, IgG2b, IgG3, IgA and IgM (anti-mouse antibodies from goat, Sigma) were diluted to 1:1000 and added to each well (100μL per well). IgG2b , IgG3suggested: NoneIgMsuggested: Noneanti-mousesuggested: NoneExperimental Models: Cell Lines Sentences Resources 1 cell line: J774A.1 cells (mouse monocyte macrophage cell line) were cultured in DMEM (dulbecco’s modified eagle medium) containing 10% fetal bovine serum (FBS) at 37°C, 5% CO2. J774A.1suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT02675439 Active, not recruiting Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in P… NCT03010176 Recruiting Study of MK-1454 Alone or in Combination With Pembrolizumab … Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
